Bo Hong

Bo Hong, MD

Languages spoken: English

  • Dr. Hong is an associate professor of clinical pathology at the University of Utah School of Medicine and is a medical director in the Cytogenetics and Genomic Microarray section at ARUP Laboratories. She received her MD from Peking University Health Science Center in China and completed a residency in internal medicine and hematology at People’s Hospital, Peking University, and a clinical cytogenetics fellowship at the University of Utah. She is board certified in Clinical Cytogenetics, and Laboratory Genetics and Genomics by the American Board of Medical Genetics and Genomics, and is a fellow of the American College of Medical Genetics and Genomics. Her academic interests include comprehensive cytogenetic and genomic characterization of hematologic malignancies, particularly childhood leukemia.

    Specialties

    • Pathology, Clinical

    Board Certification

    American Board of Medical Genetics (Clinical Cytogenetics)
    American Board of Medical Genetics and Genomics (Laboratory Genetics and Genomics)

  • Dr. Hong is an associate professor of clinical pathology at the University of Utah School of Medicine and is a medical director in the Cytogenetics and Genomic Microarray section at ARUP Laboratories. She received her MD from Peking University Health Science Center in China and completed a residency in internal medicine and hematology at People’s Hospital, Peking University, and a clinical cytogenetics fellowship at the University of Utah. She is board certified in Clinical Cytogenetics, and Laboratory Genetics and Genomics by the American Board of Medical Genetics and Genomics, and is a fellow of the American College of Medical Genetics and Genomics. Her academic interests include comprehensive cytogenetic and genomic characterization of hematologic malignancies, particularly childhood leukemia.

    Board Certification and Academic Information

    Academic Departments Pathology -Primary
    Board Certification
    American Board of Medical Genetics (Clinical Cytogenetics)
    American Board of Medical Genetics and Genomics (Laboratory Genetics and Genomics)

    Selected Publications

    Journal Article

    1. Xiaolong Alan Zhou, Jingyi Yang, Kimberly G Ringbloom, Maria Estela Martinez-Escala, Kristen E Stevenson, Alexander T Wenzel, Damiano Fantini, Haley K Martin, Andrea P Moy, Elizabeth A Morgan, Shannon Harkins, Christian N Paxton, Bo Hong, Erica F Andersen, Joan Guitart, David M Weinstock, Lorenzo Cerroni, Jaehyuk Choi, Abner Louissaint, Jr (2021). Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features. Blood Adv, 5(3), 649-661.
    2. Ballout RA, Dickerson C, Wick MJ, Al-Sweel N, Openshaw AS, Srivastava S, Swanson LC, Bramswig NC, Kuechler A, Hong B, Fleming LR, Curry K, Robertson SP, Andersen EF, El-Hattab AW (2020). Int22h1/Int22h2‐mediated Xq28 duplication syndrome: de novo duplications, prenatal diagnoses, and additional phenotypic features. Hum Mutat, 41(7), 1238-1249.
    3. Paulraj P, Diamond S, Razzaqi F, Ozeran JD, Longhurst M, Andersen EF, Toydemir RM, Hong B (2019). Pediatric acute myeloid leukemia with t(7;21)(p22;q22). Genes Chromosomes Cancer, 58(8), 551-557.
    4. Zhou XA, Louissaint, Jr A, Wenzel A, Yang J, Martinez-Escala ME, Moy AP, Morgan EA, Paxton CN, Hong B, Andersen EF, Guitart J, Behdad A, Cerroni L, Weistock DM, Choi J (2018). Genomic analyses identify recurrent alterations in immune evasion genes in diffuse large B cell lymphoma, leg type. J Investig Dermatol Symp Proc, 138(11), 2365-2376.
    5. Hong B, Zunich J, Openshaw A, Toydemir R (2017). Clinical Features of Trisomy 12 Mosaicism - Report and Review. Am J Med Genet A, 173(6), 1681-1686.
    6. Chen Z, Pasquini M, Hong B, DeHart S, Heikens M, Tsai S (2005). The human Penumbra gene is mapped to a region on chromosome 7 frequently deleted in myeloid malignancies. Cancer Genet Cytogenet, 162(2), 95-98.
    7. Liu H, Qiu JY, Lu DP, Hong B, Shi HL, Shi Y, Dang H, He Q (2003). A serial study of in cytogenetic change and morphology on the tetra-arsenic tetra-sulfide treatment in untreated or recurrent acute promyelocytic leukemia. Chin J Cancer, 25(2), 163-167.
    8. Tong CR, Hong B, Qiu JY, Chen Z, Lu DP (2002). Significance of cytogenetic and fluorescence in situ hybridization analysis in evaluating antichronic myeloid leukemia efficacy of different immune effector cells. Cancer Genet Cytogenet, 134(1), 21-4. (Read full article)
    9. Cheng SQ, Qiu JY, Lu DP, Hong B, Liu H, Dang H, He Q, Shi Y, Wang DB (2000). Detection of Minimal Residual Disease in Patients with Acute Promyelocytic Leukemia by Fluorescence in Situ Hybridization Method. Beijing Da Xue Xue Bao Yi Xue Ban, 32(1), 43-6.
    10. Hong B, Qiu JY, Dang H, Shi Y, He Q, Lu DP (1999). Application of Fluorescence in Situ Hybridization in Detecting the Formation of Variant Ph Chromosome. Beijing Da Xue Xue Bao Yi Xue Ban, 31(5), 400-3.
    11. Hong B, Qiu JY, Shi HL, He Q, Tan JH, Shi Y, Dang H, Rong YY, Wang DB, Lu DP (1998). Chromosome in Situ Suppression (CISS) Hybridization Applied to the Study of Acute Promyelocytic Leukemia. Beijing Da Xue Xue Bao Yi Xue Ban, 30(1), 29-31.
    12. Qiu JY, Chai Y, He Q, Dang H, Shi Y, Hong B, Shan FX, Wu PN, Lu DP (1997). The Evalution of Chromosome Aberration on The Patients with Myelodysplastic Syndrome: Revealment of The Pathogeny of MDS. Beijing Da Xue Xue Bao Yi Xue Ban, 29(3), 207-10.
    13. Qiu JY, Tan JH, Wang DB, Hong B, He Q, Dang H, Shi Y, Jiang B, Wu PN, Lu DP, Speicher M (1996). Detection of Acute Promyelocytic Leukemia by Morphology, Karyotype and Chromosome in Situ Suppression(CISS) Hybridizaton. 9(4), 146-9.
    14. Hong B, Qiu JY, Wang DB, Chen SS, Wu PN, Dang H, Gu JF, Shan FX, Shi HL (1995). Analysis of MIC (Morphorgy, Immunology, Cytogenetics) and Clinical Prognosis in Adult Acute Lymphoblastic Leukemia and Hybrid Leukemia. Beijing Da Xue Xue Bao Yi Xue Ban, 27(5), 343-6.
    15. Qiu JY, Hong B, Xue ZP, He Q, Zhang YQ, Lu DP (1995). Karyotype Evolution and the Effect of Graft against Leukemia. 16(2), 52-4.
    16. Qiu JY, Hong B, Wu PN, Dang H, Shan FX, Wang DB (1995). Investigation of the Aberrations of Chromosome 16 Associated with Abnormal Cytomorphology in Acute Nonlymphocytic Leukemia. 8(1), 4-7.

    Conference Proceedings

    1. Tvrdik T, Schafernak K, Jacobsen J, Toydemir R, Walsh A, Hong B (2019). Clinical and Cytogenomic Features of Lymphoblastic Leukemia with Intrachromosomal Amplification of Chromosome 21 (iAMP21) in the Context of Constitutional Ring Chromosome 21. Blood (2019) 134 (Supplement_1): 5208, Blood, 134(Supplement_1), 5208.

    Case Report

    1. Jedrzkiewicz J, Scaife E, Hong B, South S, Alashari M (April 2015). Congenital peribronchial myofibroblastic tumor: Case report and review of literature. J Pediatr Surg Case Rep, 3(4), 154-157.
    2. Chen Z, Hong B, Drozd-Borysiuk E, Coffin C, Albritton K (2004). Molecular cytogenetic characterization of a case of Mullerian adenosarcoma. Cancer Genet Cytogenet, 148(2), 129-132.
    3. Hong B, Chen Z, Coffin CM, Lemons R, Issa B, Brothman A, Zhou H (2003). Molecular cytogenetic analysis of a pleuropulmonary blastoma. Cancer Genet Cytogenet, 142(1), 65-69.
    4. Hong B, Aston E, Finlinsoni D, Miller A, Brugger C, Issa B, Brothman A, Chen Z (2001). Ider (17) in Addition to t(15;17) in A Case of Acute Promyelocytic Leukemia. J Assoc Genet Technol, 27(3), 101.

    Letter

    1. Srinivas K Tantravahi, Bryan D Huber, Jennie Vagher, Luke Maese, Anthony D Pomicter, Najla Al-Sweel, Julie D Asch, Reha M Toydemir, Bo Hong, Charles Parker (2022). Genome-wide uniparental disomy as a mechanism of immune escape in acquired aplastic anaemia. PMID: 35876645 [Letter to the editor]. British Journal of Haematology, 2022 Sep; 198(6), e78-e81.

  • News & Podcasts